Review





Similar Products

92
Miltenyi Biotec cd278 (icos) antibody, anti-human/mouse/rat, reafinity
Cd278 (Icos) Antibody, Anti Human/Mouse/Rat, Reafinity, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd278 (icos) antibody, anti-human/mouse/rat, reafinity/product/Miltenyi Biotec
Average 92 stars, based on 1 article reviews
cd278 (icos) antibody, anti-human/mouse/rat, reafinity - by Bioz Stars, 2026-05
92/100 stars
  Buy from Supplier

94
Novus Biologicals mouse igg
Mouse Igg, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse igg/product/Novus Biologicals
Average 94 stars, based on 1 article reviews
mouse igg - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

93
Novus Biologicals mca1209a647 cd34 pe pe mouse igg1
Mca1209a647 Cd34 Pe Pe Mouse Igg1, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mca1209a647 cd34 pe pe mouse igg1/product/Novus Biologicals
Average 93 stars, based on 1 article reviews
mca1209a647 cd34 pe pe mouse igg1 - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

93
Bio X Cell anti icos mab
Anti Icos Mab, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti icos mab/product/Bio X Cell
Average 93 stars, based on 1 article reviews
anti icos mab - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

93
Bio X Cell be0059
Be0059, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/be0059/product/Bio X Cell
Average 93 stars, based on 1 article reviews
be0059 - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

93
Bio X Cell a icos
A Icos, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/a icos/product/Bio X Cell
Average 93 stars, based on 1 article reviews
a icos - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

93
Bio X Cell anti icos
Anti Icos, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti icos/product/Bio X Cell
Average 93 stars, based on 1 article reviews
anti icos - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

90
Thermo Fisher mouse anti-cd278 (icos) (clone isa-3)

Mouse Anti Cd278 (Icos) (Clone Isa 3), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti-cd278 (icos) (clone isa-3)/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
mouse anti-cd278 (icos) (clone isa-3) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

92
fluidigm lag3
Opal and CODEX multiplexed tissue imaging data validate increased M2-like macrophage infiltration and T cell exhaustion in the nonrejected SCCs. A, Representative Opal Multiplex IHC stains for F4/80 (red), CD204 (yellow), and CD206 (green) in tumors derived from SCC31, SCC40, SCC32, SCC35, and SCC37 on day 10 after inoculation. Four areas from each tumor and three tumors from each SCC were examined. Scale bars, 20 μm. DAPI staining is not shown. B, Representative CODEX multiplexed tissue images for CD3 (green), CD8 (red), TIM3 (magenta), and <t>LAG3</t> (cyan blue) in tumors derived from SCC31, SCC40, SCC32, SCC35, and SCC37 on day 6 after inoculation. Five areas from each tumor and three tumors from each SCC were examined. Scale bars, 20 μm. C, Quantification of the percentage of F4/80 + CD204 + CD206 + cells described in A . Data are mean ± SEM. The rejected and nonrejected groups were compared using the Wilcoxon rank-sum test; W = 456; P = 2.55 × 10 −8 . D, Quantification of the percentage of CD3 + CD8 + cells described in B . Data are mean ± SEM. P = 0.00055; t = −5.27; degrees of freedom (df) = 9, unpaired t test. E, Quantification of the percentage of TIM3 + LAG3 + /CD3 + CD8 + cells described in B . Data are mean ± SEM. P = 0.02522; t = 2.6798; df = 9, unpaired t test. F, Boxplot quantifying the percentage of total cells for each CD8 cluster identified in CyTOF analysis. G, Boxplot quantifying the percentage of total cells for each macrophage cluster identified in CyTOF analysis. H, CFSE-based T cell proliferation assay after co-culture for 48 hours with nonrejected SCC35 tumor-derived macrophages isolated 10 days after inoculation. Representative histogram plot and quantification of CFSE intensity ( n = 5). CD8 + /CD4 + T cells isolated from healthy mouse spleens cultured without macrophages served as the controls. CD8: Kruskal–Wallis χ 2 test, χ 2 = 12.5; P = 0.001930454. Pairwise comparison by the Wilcoxon test with Bonferroni correction is shown in the figure. *, P value < 0.05. CD4: Kruskal–Wallis χ 2 test, χ 2 = 12.5; P = 0.00193. Pairwise comparison by the Wilcoxon test with Bonferroni correction is shown in the figure. *, P value < 0.05. ELISA measurement of IFNγ in culture media 48 hours after co-culture of T cells with or without tumor-derived macrophages. n = 6. Data are mean ± SEM. Kruskal–Wallis χ 2 test, χ 2 = 15.726; P = 0.0003847. Pairwise comparison by the Wilcoxon test with Bonferroni correction is shown. ***, P value < 0.01. MFI, mean fluorescence intensity.
Lag3, supplied by fluidigm, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lag3/product/fluidigm
Average 92 stars, based on 1 article reviews
lag3 - by Bioz Stars, 2026-05
92/100 stars
  Buy from Supplier

Image Search Results


Journal: Cell Reports Medicine

Article Title: T-bet+ CXCR3+ B cells drive hyperreactive B-T cell interactions in multiple sclerosis

doi: 10.1016/j.xcrm.2025.102027

Figure Lengend Snippet:

Article Snippet: Mouse anti-CD278 (ICOS) (clone ISA-3); (FACS, in vitro ) , Thermo Fisher Scientific , Cat# 17-9948-41; RRID: AB_10597585.

Techniques: In Vitro, Control, Recombinant, Staining, Purification, Electron Microscopy, Lysis, Ubiquitin Proteomics, Cell Isolation, Enzyme-linked Immunosorbent Assay, Isolation, Multiplex Assay, Quantitation Assay, Modification, Library Quantification, RNA Sequencing, Sequencing, Software, Cell Culture, Sterility

Opal and CODEX multiplexed tissue imaging data validate increased M2-like macrophage infiltration and T cell exhaustion in the nonrejected SCCs. A, Representative Opal Multiplex IHC stains for F4/80 (red), CD204 (yellow), and CD206 (green) in tumors derived from SCC31, SCC40, SCC32, SCC35, and SCC37 on day 10 after inoculation. Four areas from each tumor and three tumors from each SCC were examined. Scale bars, 20 μm. DAPI staining is not shown. B, Representative CODEX multiplexed tissue images for CD3 (green), CD8 (red), TIM3 (magenta), and LAG3 (cyan blue) in tumors derived from SCC31, SCC40, SCC32, SCC35, and SCC37 on day 6 after inoculation. Five areas from each tumor and three tumors from each SCC were examined. Scale bars, 20 μm. C, Quantification of the percentage of F4/80 + CD204 + CD206 + cells described in A . Data are mean ± SEM. The rejected and nonrejected groups were compared using the Wilcoxon rank-sum test; W = 456; P = 2.55 × 10 −8 . D, Quantification of the percentage of CD3 + CD8 + cells described in B . Data are mean ± SEM. P = 0.00055; t = −5.27; degrees of freedom (df) = 9, unpaired t test. E, Quantification of the percentage of TIM3 + LAG3 + /CD3 + CD8 + cells described in B . Data are mean ± SEM. P = 0.02522; t = 2.6798; df = 9, unpaired t test. F, Boxplot quantifying the percentage of total cells for each CD8 cluster identified in CyTOF analysis. G, Boxplot quantifying the percentage of total cells for each macrophage cluster identified in CyTOF analysis. H, CFSE-based T cell proliferation assay after co-culture for 48 hours with nonrejected SCC35 tumor-derived macrophages isolated 10 days after inoculation. Representative histogram plot and quantification of CFSE intensity ( n = 5). CD8 + /CD4 + T cells isolated from healthy mouse spleens cultured without macrophages served as the controls. CD8: Kruskal–Wallis χ 2 test, χ 2 = 12.5; P = 0.001930454. Pairwise comparison by the Wilcoxon test with Bonferroni correction is shown in the figure. *, P value < 0.05. CD4: Kruskal–Wallis χ 2 test, χ 2 = 12.5; P = 0.00193. Pairwise comparison by the Wilcoxon test with Bonferroni correction is shown in the figure. *, P value < 0.05. ELISA measurement of IFNγ in culture media 48 hours after co-culture of T cells with or without tumor-derived macrophages. n = 6. Data are mean ± SEM. Kruskal–Wallis χ 2 test, χ 2 = 15.726; P = 0.0003847. Pairwise comparison by the Wilcoxon test with Bonferroni correction is shown. ***, P value < 0.01. MFI, mean fluorescence intensity.

Journal: Cancer Discovery

Article Title: Temporal Genomic Analysis of Homogeneous Tumor Models Reveals Key Regulators of Immune Evasion in Melanoma

doi: 10.1158/2159-8290.CD-23-1422

Figure Lengend Snippet: Opal and CODEX multiplexed tissue imaging data validate increased M2-like macrophage infiltration and T cell exhaustion in the nonrejected SCCs. A, Representative Opal Multiplex IHC stains for F4/80 (red), CD204 (yellow), and CD206 (green) in tumors derived from SCC31, SCC40, SCC32, SCC35, and SCC37 on day 10 after inoculation. Four areas from each tumor and three tumors from each SCC were examined. Scale bars, 20 μm. DAPI staining is not shown. B, Representative CODEX multiplexed tissue images for CD3 (green), CD8 (red), TIM3 (magenta), and LAG3 (cyan blue) in tumors derived from SCC31, SCC40, SCC32, SCC35, and SCC37 on day 6 after inoculation. Five areas from each tumor and three tumors from each SCC were examined. Scale bars, 20 μm. C, Quantification of the percentage of F4/80 + CD204 + CD206 + cells described in A . Data are mean ± SEM. The rejected and nonrejected groups were compared using the Wilcoxon rank-sum test; W = 456; P = 2.55 × 10 −8 . D, Quantification of the percentage of CD3 + CD8 + cells described in B . Data are mean ± SEM. P = 0.00055; t = −5.27; degrees of freedom (df) = 9, unpaired t test. E, Quantification of the percentage of TIM3 + LAG3 + /CD3 + CD8 + cells described in B . Data are mean ± SEM. P = 0.02522; t = 2.6798; df = 9, unpaired t test. F, Boxplot quantifying the percentage of total cells for each CD8 cluster identified in CyTOF analysis. G, Boxplot quantifying the percentage of total cells for each macrophage cluster identified in CyTOF analysis. H, CFSE-based T cell proliferation assay after co-culture for 48 hours with nonrejected SCC35 tumor-derived macrophages isolated 10 days after inoculation. Representative histogram plot and quantification of CFSE intensity ( n = 5). CD8 + /CD4 + T cells isolated from healthy mouse spleens cultured without macrophages served as the controls. CD8: Kruskal–Wallis χ 2 test, χ 2 = 12.5; P = 0.001930454. Pairwise comparison by the Wilcoxon test with Bonferroni correction is shown in the figure. *, P value < 0.05. CD4: Kruskal–Wallis χ 2 test, χ 2 = 12.5; P = 0.00193. Pairwise comparison by the Wilcoxon test with Bonferroni correction is shown in the figure. *, P value < 0.05. ELISA measurement of IFNγ in culture media 48 hours after co-culture of T cells with or without tumor-derived macrophages. n = 6. Data are mean ± SEM. Kruskal–Wallis χ 2 test, χ 2 = 15.726; P = 0.0003847. Pairwise comparison by the Wilcoxon test with Bonferroni correction is shown. ***, P value < 0.01. MFI, mean fluorescence intensity.

Article Snippet: The samples were stained with TIM3 (Standard BioTools, Cat. #3162029, RRID: AB_2687841), CD8 (Standard BioTools, Cat. #3153012B, RRID: AB_2885019), Cx3cr1 (Standard BioTools, Cat. #92J020155, RRID: AB_3665151), CD62L (Standard BioTools, Cat. #3160008, RRID: AB_2687840), TCRβ (Fluidigm, Cat. #3143010B, RRID: AB_3665159), CD3 (Standard BioTools, Cat. #3152004, RRID: AB_2687836), CTLA-4 (Fluidigm, Cat. #3154008B, RRID: AB_3665152), PD-1 (Standard BioTools, Cat. #3159024, RRID: AB_2687839), CD44 (Standard BioTools, Cat. #3171003B, RRID: AB_2895121), GrnzB (Standard BioTools, Cat #3173006B, RRID: AB_2811095), Lag3 (Standard BioTools, Cat. #3174019B, RRID: AB_3665154), ICOS (Fluidigm, Cat. #3176014B, RRID: AB_3665155), CD4 (Standard BioTools, Cat. #3145002B, RRID: AB_2687832), CCR7 (Standard BioTools, Cat. #92J015163, RRID: AB_3665153), CD25 (Standard BioTools, Cat. #3151007B, RRID: AB_2827880), Foxp3 (Standard BioTools, Cat. #3165024, RRID: AB_2687843), MHC-II (Standard BioTools, Cat. #3209006B, RRID: AB_2885025), iNOS (Standard BioTools, Cat. #3161011B, RRID: AB_2922920), CD80 (Fluidigm, Cat. #92J023158, RRID: AB_3665158), F480 (Standard BioTools, Cat. #3146008B, RRID: AB_2895117), CD11b (Standard BioTools, Cat. #3148003B, RRID: AB_2814738), Ly6C (Standard BioTools, Cat. #3150010B, RRID: AB_2895118), CD206 (Standard BioTools, Cat. #3169021B, RRID: AB_2832249), CD86 (Standard BioTools, Cat. #3172016B, RRID: AB_2922923), and Ki67 (Standard BioTools, Cat. #3168007B, RRID: AB_2800467).

Techniques: Imaging, Multiplex Assay, Derivative Assay, Staining, Proliferation Assay, Co-Culture Assay, Isolation, Cell Culture, Comparison, Enzyme-linked Immunosorbent Assay, Fluorescence

The decreased growth of Mif KO tumors is mediated by CD8 + T cells characterized by less exhaustion and high proliferation. A, Representative Opal Multiplex IHC stains for F4/80 (red), CD204 (yellow), and CD206 (green) in tumors derived from Mif WT or KO SCC35 on day 10 after inoculation. Four areas from each tumor and three tumors from each SCC were examined. Scale bars, 20 μm. DAPI staining is not shown. B, Quantification of the percentage of F4/80 + CD204 + CD206 + cells described in A . Data are mean ± SEM. P = 0.0012; t = −10.411; degrees of freedom (df) = 3.28, unpaired t test. C, Representative CODEX multiplexed tissue images for CD3 (green), CD8 (red), TIM3 (magenta), and LAG3 (cyan blue) in tumors derived from Mif WT or KO SCC35 on day 10 after inoculation. Five areas from each tumor and three and four tumors from Mif KO and Mif WT, respectively, were examined. Scale bars, 20 μm. D, Quantification of the percentage of CD3 + CD8 + T cells described in C . Data are mean ± SEM. P = 0.05732; t = 3.8252; df = 4, unpaired t test. E, Quantification of the percentage of TIM3 + LAG3 + /CD3 + CD8 + T cells described in C . Data are mean ± SEM. P = 0.004664; t = −6.0229; df = 3.759, unpaired t test. F, Growth curve of tumors derived from Mif KO clones (left: SCC37 KO clone 21; right: SCC35 KO clone 24) in immunocompetent mice, treated with anti-CD8 antibody or IgG control. n = 8–9. Pairwise comparisons using the Wilcoxon rank-sum test. P = 2.2 × 10 −5 and 0.00058, respectively.

Journal: Cancer Discovery

Article Title: Temporal Genomic Analysis of Homogeneous Tumor Models Reveals Key Regulators of Immune Evasion in Melanoma

doi: 10.1158/2159-8290.CD-23-1422

Figure Lengend Snippet: The decreased growth of Mif KO tumors is mediated by CD8 + T cells characterized by less exhaustion and high proliferation. A, Representative Opal Multiplex IHC stains for F4/80 (red), CD204 (yellow), and CD206 (green) in tumors derived from Mif WT or KO SCC35 on day 10 after inoculation. Four areas from each tumor and three tumors from each SCC were examined. Scale bars, 20 μm. DAPI staining is not shown. B, Quantification of the percentage of F4/80 + CD204 + CD206 + cells described in A . Data are mean ± SEM. P = 0.0012; t = −10.411; degrees of freedom (df) = 3.28, unpaired t test. C, Representative CODEX multiplexed tissue images for CD3 (green), CD8 (red), TIM3 (magenta), and LAG3 (cyan blue) in tumors derived from Mif WT or KO SCC35 on day 10 after inoculation. Five areas from each tumor and three and four tumors from Mif KO and Mif WT, respectively, were examined. Scale bars, 20 μm. D, Quantification of the percentage of CD3 + CD8 + T cells described in C . Data are mean ± SEM. P = 0.05732; t = 3.8252; df = 4, unpaired t test. E, Quantification of the percentage of TIM3 + LAG3 + /CD3 + CD8 + T cells described in C . Data are mean ± SEM. P = 0.004664; t = −6.0229; df = 3.759, unpaired t test. F, Growth curve of tumors derived from Mif KO clones (left: SCC37 KO clone 21; right: SCC35 KO clone 24) in immunocompetent mice, treated with anti-CD8 antibody or IgG control. n = 8–9. Pairwise comparisons using the Wilcoxon rank-sum test. P = 2.2 × 10 −5 and 0.00058, respectively.

Article Snippet: The samples were stained with TIM3 (Standard BioTools, Cat. #3162029, RRID: AB_2687841), CD8 (Standard BioTools, Cat. #3153012B, RRID: AB_2885019), Cx3cr1 (Standard BioTools, Cat. #92J020155, RRID: AB_3665151), CD62L (Standard BioTools, Cat. #3160008, RRID: AB_2687840), TCRβ (Fluidigm, Cat. #3143010B, RRID: AB_3665159), CD3 (Standard BioTools, Cat. #3152004, RRID: AB_2687836), CTLA-4 (Fluidigm, Cat. #3154008B, RRID: AB_3665152), PD-1 (Standard BioTools, Cat. #3159024, RRID: AB_2687839), CD44 (Standard BioTools, Cat. #3171003B, RRID: AB_2895121), GrnzB (Standard BioTools, Cat #3173006B, RRID: AB_2811095), Lag3 (Standard BioTools, Cat. #3174019B, RRID: AB_3665154), ICOS (Fluidigm, Cat. #3176014B, RRID: AB_3665155), CD4 (Standard BioTools, Cat. #3145002B, RRID: AB_2687832), CCR7 (Standard BioTools, Cat. #92J015163, RRID: AB_3665153), CD25 (Standard BioTools, Cat. #3151007B, RRID: AB_2827880), Foxp3 (Standard BioTools, Cat. #3165024, RRID: AB_2687843), MHC-II (Standard BioTools, Cat. #3209006B, RRID: AB_2885025), iNOS (Standard BioTools, Cat. #3161011B, RRID: AB_2922920), CD80 (Fluidigm, Cat. #92J023158, RRID: AB_3665158), F480 (Standard BioTools, Cat. #3146008B, RRID: AB_2895117), CD11b (Standard BioTools, Cat. #3148003B, RRID: AB_2814738), Ly6C (Standard BioTools, Cat. #3150010B, RRID: AB_2895118), CD206 (Standard BioTools, Cat. #3169021B, RRID: AB_2832249), CD86 (Standard BioTools, Cat. #3172016B, RRID: AB_2922923), and Ki67 (Standard BioTools, Cat. #3168007B, RRID: AB_2800467).

Techniques: Multiplex Assay, Derivative Assay, Staining, Clone Assay, Control